

Appl. No. : 09/380,534
Filed : September 1, 1999

This election is made without traverse. Applicants reserve the right to prosecute Claims pertaining to non-elected Group 2 and Group 1, Species 1 and 3-5 in divisional applications, if necessary, under the provisions of 35 USC 121.

Further, please amend the above-identified application as follows:

IN THE CLAIMS

Kindly amend Claims 1, 4, 9-11, 14, and 48 as set forth below:

1. (Amended) A method of inducing and/or sustaining an immunological CTL response in a mammal, which method comprises:

delivering an antigen to the mammal at a level sufficient to induce an immunologic CTL response in the mammal; and

maintaining the antigen in the mammal's lymphatic system over time sufficient to maintain the immunologic CTL response.

4. (Amended) The method of Claim 1, wherein the method is applied to a treatment of a mammal having a disease, or being predisposed to a disease, wherein the antigen is a disease-matched antigen.

9. (Amended) The method of Claim 4 wherein a single antigen is delivered to the mammal.

10. (Amended) The method of Claim 4 wherein multiple antigens are delivered to the mammal.

11. (Amended) The method of Claim 4 wherein the CTL response is maintained by delivering the antigen directly to the mammal's lymphatic system.

14. (Amended) The method of Claim 4 wherein the antigen is delivered to the mammal by pumping a physiologically-acceptable composition of the antigen from a device held external of the mammal's body through a transmission line and catheter positioned to deliver the antigen-containing composition so that the antigen reaches the mammal's lymph system.

48. (Amended) The method of claim 1, wherein said antigen is provided as a nucleic acid encoding the antigen.

Kindly add the add new Claims 61-65 as set forth below:

61. (New) The method of Claim 1, wherein the antigen is delivered as a bolus in a single dose, and wherein the single dose is sufficient to maintain the immunologic CTL response.
62. (New) The method of Claim 1, wherein the antigen is maintained by sustained, regular delivery of the antigen.
63. (New) The method of Claim 4, wherein the level of antigen is sufficient to induce an increased CTL-response in the mammal.
64. (New) The method of Claim 4, wherein the maintaining step extends for a time sufficient to treat the disease.
65. (New) The method of Claim 4, wherein the antigen is maintained in the lymphatic system by sustained, regular delivery of the disease-matched antigen.

REMARKS

This Amendment is submitted in response to the Office Action mailed January 24, 2001. Claims 1, 4, 9-11, 14, and 48 have been amended. Support for the amendment to Claim 1 is found in the specification at page 9, line 26 to page 10, line 3. Support for the amendment to Claim 4 is found in the Claim as originally filed. Support for the amendment to Claims 9-11 and 14 is found in the original claims. Claim 48 has been amended to correct a typographical error.

The specific changes to the amended claims are shown on a separate set of pages attached hereto and titled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment and Response to Restriction Requirement. On this set of pages, the **insertions are underlined and in bold** while the [deletions are in brackets and in bold typeface].

New Claims 61-65 have been added. Support is found in the claims as originally filed and in the specification at pages 9 and 10. Additional support for new Claim 61 is found in Examples 4 and 5. Consideration of new Claims 61-65 is respectfully requested. No other changes have been made and no new matter has been added.

All of the amendments made herein are directed to clarification of the claimed subject matter and/or to further particularity in claiming embodiments of the invention. There is no amendment made with reference to any prior art.